FORM 3

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Date of Event 3. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person\* Requiring Statement TANDEM DIABETES CARE INC [ TNDM ] HLM VENTURE PARTNERS II, (Month/Day/Year) 11/13/2013 **L.P.** 4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of Original Filed (Check all applicable) (Month/Day/Year) (Last) (First) (Middle) X 10% Owner Director 222 BERKELEY STREET Officer (give title Other (specify 6. Individual or Joint/Group Filing (Check below) below) Applicable Line) Form filed by One Reporting Person (Street) Form filed by More than One **BOSTON** 02116 MA Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial Ownership Form: Direct (D) Beneficially Owned (Instr. 4) (Instr. 5) or Indirect (I) (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and 3. Title and Amount of Securities 6. Nature of Indirect Expiration Date (Month/Day/Year) Underlying Derivative Security (Instr. 4) Conversion Ownership Beneficial Ownership (Instr. 5) or Exercise Form: Price of Direct (D) Amount or Derivative or Indirect (I) (Instr. 5) Expiration Number of Security Title Exercisable Date Shares (1) (2)  $D^{(3)}$ Series C Preferred Stock Common Stock 223,684 0.00 (1) (2)  $D^{(3)}$ Series D Preferred Stock Common Stock 1,230,374 0.00 Preferred Stock Warrant (4) Series D Preferred Stock(5) 87,662(5) 4.4(5)  $\mathbf{D}^{(3)}$ 08/17/2021  $D^{(3)}$ Preferred Stock Warrant (4) 05/25/2022 Series D Preferred Stock<sup>(6)</sup> 21,915(6)  $4.4^{(6)}$ Series D Preferred Stock(7) 33,014(7) 4.4(7)  $D^{(3)}$ 17/2022

Preferred Stock Warrant		(4)	07/1	
	ess of Reporting Perso			
(Last) 222 BERKELE	(First) Y STREET	(Middle)		
				-
(Street) BOSTON	MA	02116		
(City)	(State)	(Zip)		
	ess of Reporting Personer Associates II			
(Last) 222 BERKELE	(First) Y STREET	(Middle)		
(Street) BOSTON	MA	02116		
(City)	(State)	(Zip)		
1. Name and Addre	ess of Reporting Person	on*		
(Last) C/O HLM VEN	(First) VTURE PARTNER	(Middle)		

222 BERKELEY STREET

-					
(Street)					
BOSTON	MA	02116			
(0)	(0: + )	(T: )	_		
(City)	(State)	(Zip)			
1. Name and Addr	ess of Reporting Person*				
<b>GRUA PET</b>	ER J				
(Last)	(First)	(Middle)			
C/O HLM VENTURE PARTNERS					
222 BERKELEY STREET					
(Street)					
BOSTON	MA	02116			
(City)	(State)	(Zip)			
1. Name and Addr	ess of Reporting Person*				
RAY RUSS	ELL T				
-					
(Last)	(First)	(Middle)			
C/O HLM VENTURE PARTNERS					
222 BERKELE	EY STREET				
(Street)					
BOSTON	MA	02116			
	IVIA	02110			
(City)	(State)	(Zip)			
. 97	( )	. 17			

### **Explanation of Responses:**

- 1. The securities are immediately convertible.
- 2. The expiration date is not relevant to the conversion of these securities.
- 3. The reported securities are owned by HLM Venture Partners II, L.P. HLM Venture Associates II, L.L.C. (the "General Partner"), and Edward L. Cahill, Peter J. Grua and Russell T. Ray, the managing members of the General Partner, may be deemed to share voting and dispositive power over the reported securities but each disclaims beneficial ownership in the securities held by HLM Venture Partners II, L.P., except to the extent of their pecuniary interest therein.
- 4. The warrants are immediately exercisable.
- 5. Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 52,316 shares of the Issuer's common stock at an exercise price of \$4.40 per share.
- 6. Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 13,078 shares of the Issuer's common stock at an exercise price of \$4.40 per share.
- 7. Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 19,702 shares of the Issuer's common stock at an exercise price of \$4.40 per share.

### Remarks:

/s/ David B. Berger, Attorney- in-Fact for HLM Venture Partners II, L.P.	11/13/2013
/s/ David B. Berger, Attorney- in-Fact for HLM Venture Associates II, L.L.C.	11/13/2013
/s/ David B. Berger, Attorney- in-Fact for Edward L. Cahill	11/13/2013
/s/ David B. Berger, Attorney- in-Fact for Peter J. Grua	11/13/2013
/s/ David B. Berger, Attorney- in-Fact for Russell T. Ray	11/13/2013
** Signature of Reporting Person	Date

 $Reminder: \ Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned hereby constitutes and appoints David B. Berger, John Cajigas, Leigh Vosseller and Bruce Feuchter, or any of them signing individually, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as the beneficial owner of more than ten percent (10.0%) of any class of any equity security of Tandem Diabetes Care, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4s and 5s and timely file such form with the SEC and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to each such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments thereto) and agrees to reimburse the Company and each such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned have caused this Power of Attorney to be executed as of this 11th day of November 2013.

HLM VENTURE PARTNERS II, L.P.
By: HLM Venture Associates II, L.L.C.
Its: General Partner
/s/ Vincent J. Fabiani, Authorized Signer
HLM VENTURE ASSOCIATES II, L.L.C.
/s/ Vincent J. Fabiani, Authorized Signer
/s/ Edward L. Cahill, an individual
/s/ Peter J. Grua, an individual

/s/ Russell T. Ray, an individual